ASX:4DXHealthcare Services
Is 4DMedical’s (ASX:4DX) GSK Imaging Deal a Clue to Its Evolving Business Model?
4DMedical Limited recently announced a one-year contractual engagement, commencing 1 May 2026, to provide its proprietary quantitative lung imaging analytics to GlaxoSmithKline, in association with Flywheel Exchange, in support of pulmonary drug development and clinical research.
This agreement with one of the world’s large pharmaceutical companies adds to 4DMedical’s existing biopharma relationships and underlines growing use of its lung imaging platform in clinical trials.
We’ll now...